
Quarterly report 2023-Q3
added 11-07-2023
Eargo Cash Flow 2011-2026 | EAR
Annual Cash Flow Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-117 M | -98.5 M | -26 M | -39.1 M | -27.1 M | - | - | - | - | - | - | - |
Depreciation & Amortization |
5.46 M | 4.2 M | 2.52 M | 1.53 M | 695 K | - | - | - | - | - | - | - |
Accounts Payables |
6.5 M | 9.05 M | 6.02 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
1.91 M | 12.5 M | 3.79 M | - | - | - | - | - | - | - | - | - |
Total Inventories |
5.04 M | 5.71 M | 2.74 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -21.3 M | - | -96.9 M | -82.9 M | -20.4 M | - | -53.5 M | -31.4 M | -9.31 M | - | -20.1 M | -16 M | -9.55 M | - | -29.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
100 K | 100 K | 1.28 M | - | 200 K | 200 K | 1.42 M | - | 1.4 M | 700 K | 700 K | - | 700 K | 600 K | 565 K | - | 400 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
5.05 M | 3.73 M | 8.98 M | 6.5 M | 6.4 M | 8.37 M | 12 M | 9.05 M | 11 M | 6.76 M | 6.6 M | 6.02 M | 6.02 M | 6.02 M | 6.02 M | 5.43 M | 5.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
1.01 M | 961 K | 1.92 M | 1.91 M | 1.16 M | 12.2 M | 12.3 M | 12.5 M | 15 M | 15.4 M | 5.34 M | 3.79 M | 3.79 M | 3.79 M | 3.79 M | 2.05 M | 2.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
4.39 M | 5.36 M | 4.84 M | 5.04 M | 4.95 M | 6.82 M | 5.79 M | 5.71 M | 6.27 M | 3.2 M | 2.46 M | 2.74 M | 2.74 M | 2.74 M | 2.74 M | 2.88 M | 2.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Eargo, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
$ 2.2 | -1.78 % | $ 3.43 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 10.41 | -0.62 % | $ 1.41 B | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Align Technology
ALGN
|
$ 179.0 | 3.82 % | $ 13.4 B | ||
|
Alphatec Holdings
ATEC
|
$ 12.53 | -0.28 % | $ 1.88 B | ||
|
AxoGen
AXGN
|
$ 31.47 | 1.7 % | $ 1.45 B | ||
|
Butterfly Network
BFLY
|
$ 3.94 | -0.25 % | $ 834 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
Bio-Rad Laboratories
BIO
|
$ 269.49 | 0.5 % | $ 7.6 B | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
$ 34.4 | 1.09 % | $ 5.13 K | ||
|
Boston Scientific Corporation
BSX
|
$ 71.7 | 0.58 % | $ 106 B | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
$ 9.27 | -3.49 % | $ 262 M | ||
|
CONMED Corporation
CNMD
|
$ 36.91 | 0.6 % | $ 1.15 B | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.68 | 3.83 % | $ 37 M | ||
|
Delcath Systems
DCTH
|
$ 9.37 | -0.11 % | $ 336 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.92 | - | $ 146 M | ||
|
Electromed
ELMD
|
$ 23.17 | -0.64 % | $ 196 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 65.71 | 0.32 % | $ 1.95 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 83.0 | 0.42 % | $ 48.5 B | ||
|
FONAR Corporation
FONR
|
$ 18.46 | 0.11 % | $ 121 M | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
$ 86.85 | 0.29 % | $ 11.7 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Helius Medical Technologies
HSDT
|
$ 2.06 | -0.48 % | $ 1.25 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 8.96 | 0.63 % | $ 690 M | ||
|
Inogen
INGN
|
$ 6.09 | -0.65 % | $ 162 M | ||
|
InMode Ltd.
INMD
|
$ 13.6 | 1.12 % | $ 879 M | ||
|
Inspire Medical Systems
INSP
|
$ 57.17 | 1.28 % | $ 1.68 B | ||
|
IRIDEX Corporation
IRIX
|
$ 1.33 | - | $ 21.5 M | ||
|
IRadimed Corporation
IRMD
|
$ 100.8 | 1.13 % | $ 1.28 B | ||
|
Integer Holdings Corporation
ITGR
|
$ 85.11 | 0.48 % | $ 2.96 B | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 16.67 | 0.06 % | $ 391 M |